Acadia Pharmaceuticals Net Debt Growth & History (ACAD)
Acadia Pharmaceuticals's net debt was −$125.5M for fiscal 2025.
View full Acadia Pharmaceuticals company overviewAcadia Pharmaceuticals annual net debt history
| Fiscal year | Period ended | Net debt | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | −$125.5M | $142.1M | — |
| 2024 | 2024-12-31 | −$267.6M | −$136.1M | — |
| 2023 | 2023-12-31 | −$131.5M | −$78.6M | — |
| 2022 | 2022-12-31 | −$52.8M | $30.2M | — |
| 2021 | 2021-12-31 | −$83.0M | $193.5M | — |
| 2020 | 2020-12-31 | −$276.5M | −$96.6M | — |
| 2019 | 2019-12-31 | −$179.9M | −$45.1M | — |
| 2018 | 2018-12-31 | −$134.8M | — | — |
| 2011 | 2011-12-31 | −$6.8M | −$54,000 | — |
| 2010 | 2010-12-31 | −$6.8M | — | — |
Acadia Pharmaceuticals quarterly net debt
| Fiscal quarter | Period ended | Net debt | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | −$311.1M | −$113.8M | — |
| Q1 2026 | 2026-03-31 | −$231.4M | −$69.7M | — |
| Q4 2025 | 2025-12-31 | −$125.5M | $142.1M | — |
| Q3 2025 | 2025-09-30 | −$203.2M | −$97.4M | — |
| Q2 2025 | 2025-06-30 | −$197.3M | −$77.9M | — |
| Q1 2025 | 2025-03-31 | −$161.7M | −$16.6M | — |
| Q4 2024 | 2024-12-31 | −$267.6M | −$136.1M | — |
| Q3 2024 | 2024-09-30 | −$105.8M | −$64.7M | — |
| Q2 2024 | 2024-06-30 | −$119.5M | −$70.4M | — |
| Q1 2024 | 2024-03-31 | −$145.1M | $85.2M | — |
| Q4 2023 | 2023-12-31 | −$131.5M | −$78.6M | — |
| Q3 2023 | 2023-09-30 | −$41.1M | $50.8M | — |
| Q2 2023 | 2023-06-30 | −$49.1M | $27.0M | — |
| Q1 2023 | 2023-03-31 | −$230.3M | −$89.8M | — |
| Q4 2022 | 2022-12-31 | −$52.8M | $30.2M | — |
| Q3 2022 | 2022-09-30 | −$91.8M | −$63.0M | — |
| Q2 2022 | 2022-06-30 | −$76.1M | $124.2M | — |
| Q1 2022 | 2022-03-31 | −$140.5M | $97.3M | — |
| Q4 2021 | 2021-12-31 | −$83.0M | $193.5M | — |
| Q3 2021 | 2021-09-30 | −$28.8M | $374.3M | — |
| Q2 2021 | 2021-06-30 | −$200.3M | $101.8M | — |
| Q1 2021 | 2021-03-31 | −$237.8M | −$73.8M | — |
| Q4 2020 | 2020-12-31 | −$276.5M | −$96.6M | — |
| Q3 2020 | 2020-09-30 | −$403.2M | −$27.9M | — |
| Q2 2020 | 2020-06-30 | −$302.1M | −$238.8M | — |
| Q1 2020 | 2020-03-31 | −$164.1M | −$77.7M | — |
| Q4 2019 | 2019-12-31 | −$179.9M | −$45.1M | — |
| Q3 2019 | 2019-09-30 | −$375.2M | — | — |
| Q2 2019 | 2019-06-30 | −$63.3M | — | — |
| Q1 2019 | 2019-03-31 | −$86.3M | — | — |
| Q4 2018 | 2018-12-31 | −$134.8M | — | — |
| Q3 2012 | 2012-09-30 | −$8.0M | $267,000 | — |
| Q2 2012 | 2012-06-30 | −$9.2M | −$1.2M | — |
| Q1 2012 | 2012-03-31 | −$5.5M | — | — |
| Q4 2011 | 2011-12-31 | −$6.8M | −$54,000 | — |
| Q3 2011 | 2011-09-30 | −$8.3M | — | — |
| Q2 2011 | 2011-06-30 | −$8.0M | — | — |
| Q4 2010 | 2010-12-31 | −$6.8M | — | — |
Acadia Pharmaceuticals net debt trends
Over the last five fiscal years, Acadia Pharmaceuticals's net debt increased from −$276.5M to −$125.5M, a change of $151.0M. The latest reported quarter, Q2 2026, shows −$311.1M.
What net debt means
Net debt compares a company’s interest-bearing debt with its cash and cash equivalents. Positive net debt means debt exceeds cash, while a negative value indicates the company has more cash than debt on this measure.
How net debt is calculated
TickerStat calculates net debt as total interest-bearing debt minus cash and cash equivalents at the same reporting-period end. Short-term investments are not subtracted because they are not included in the standardized cash series. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Acadia Pharmaceuticals source filings ↗